LMAT Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of -12425.36%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

LeMaitre Vascular, Inc. has a consensus price target of $104.33, signalling upside risk potential of 21.74%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 414.97%. Given that Perspective Therapeutics, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.93%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.88x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.28x versus 162.05x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integra LifeSciences Holdings Corp. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of -1.34%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

LeMaitre Vascular, Inc. has a consensus price target of $104.33, signalling upside risk potential of 21.74%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 14.22%. Given that LeMaitre Vascular, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe LeMaitre Vascular, Inc. is more attractive than Integra LifeSciences Holdings Corp..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.93%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.88x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.28x versus 0.63x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of 26.1%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat ResMed, Inc.'s return on equity of 25.6%.

LeMaitre Vascular, Inc. has a consensus price target of $104.33, signalling upside risk potential of 21.74%. On the other hand ResMed, Inc. has an analysts' consensus of $293.47 which suggests that it could grow by 16.68%. Given that LeMaitre Vascular, Inc. has higher upside potential than ResMed, Inc., analysts believe LeMaitre Vascular, Inc. is more attractive than ResMed, Inc..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.93%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. LeMaitre Vascular, Inc.'s net income of $17.4M is lower than ResMed, Inc.'s net income of $348.5M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.88x while ResMed, Inc.'s PE ratio is 25.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.28x versus 7.04x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 28.44% compared to LeMaitre Vascular, Inc.'s net margin of 3.93%. LeMaitre Vascular, Inc.'s return on equity of 15.17% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

LeMaitre Vascular, Inc. has a consensus price target of $104.33, signalling upside risk potential of 21.74%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 145.78%. Given that Xtant Medical Holdings, Inc. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than LeMaitre Vascular, Inc..

LeMaitre Vascular, Inc. has a beta of 0.676, which suggesting that the stock is 32.402% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

LeMaitre Vascular, Inc. has a quarterly dividend of $0.20 per share corresponding to a yield of 0.93%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular, Inc. pays 33.1% of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular, Inc. quarterly revenues are $61M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. LeMaitre Vascular, Inc.'s net income of $17.4M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, LeMaitre Vascular, Inc.'s price-to-earnings ratio is 36.88x while Xtant Medical Holdings, Inc.'s PE ratio is 59.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular, Inc. is 8.28x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.